Insta
Mumbai Based Pharmaceutical Giant Cipla Partners With Govt Labs To Produce Effective Drugs For Covid-19
Cipla Head Office. (Alyssa Banta/Newsmakers)
Mumbai based pharmaceutical giant Cipla has embarked on fast-tracked development of drugs to cure COVID-19 in partnership with Government laboratories, while repurposing its gamut of respiratory, asthma, antivirals and HIV drugs to defeat the spread of COVID-19 in India, reports Times of India.
It should also be noted that Cipla's drug Actemra which is used in treating rheumatoid arthritis was recently approved by China for usage in the treatment of patients with severe complications associated with COVID-19.
Known for many innovations in respiratory, HIV and flu therapy, Cipla's promoter Yusuf Hamied said, "We consider it a nationalistic duty to put up all our resources to benefit the country."
The company, which was one of the first ones to launch a generic cure to H1N1 influenza is now aiming to become the first domestic company to introduce drugs against COVID-19.
The company is presently looking into the production of raw materials with the help of Government laboratories for antiviral compounds like favipiravir, remidesivir and bolaxavir. It should be noted though that the final drugs will take about six months to be launched after the procurement of raw materials (active pharmaceutical ingredients) begins.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest
